Analyst Reco. AbbVie Inc.

Equities

ABBV

US00287Y1091

Pharmaceuticals

Real-time Estimate Cboe BZX Other stock markets 20:22:07 15/04/2026 BST			5-day change	1st Jan Change
208.76 ^USD	+0.11%		-1.32%	-8.62%

05:07pm	Johnson & Johnson Reported Above-Peer Topline Growth in Q1, BofA Says	MT
10:11am	RemeGen Receives $650 Million Upfront Payment From AbbVie Under Licensing Agreement	MT

Analyst Reco.

05:07pm	Johnson & Johnson Reported Above-Peer Topline Growth in Q1, BofA Says	MT
04-13	Evercore ISI Adjusts AbbVie Price Target to $232 From $233, Maintains Outperform Rating	MT
04-10	AbbVie First-Quarter Earnings Unlikely to Lift Sentiment, RBC Says	MT
04-10	Guggenheim Adjusts Price Target on AbbVie to $249 From $242, Maintains Buy Rating	MT
04-09	Biopharma Stocks Largely Exempt From Pharma Tariffs, BofA Says	MT
04-08	Cantor Fitzgerald Adjusts Price Target on AbbVie to $240 From $250, Maintains Overweight Rating	MT
03-09	Global markets live: Live Nation, Eli Lilly, Amazon, Microsoft, ABB…
03-05	Evercore ISI Adjusts AbbVie Price Target to $233 From $228, Maintains Outperform Rating	MT
02-25	AbbVie Could See Continued Outperformance Despite Market Concerns, RBC Capital Markets Says	MT
02-19	Daiwa Securities Raises AbbVie Price Target to $244 From $226, Maintains Outperform Rating	MT
02-18	Piper Sandler Adjusts Price Target on AbbVie to $299 From $289, Maintains Overweight Rating	MT
02-17	HSBC Adjusts Price Target on AbbVie to $275 From $265, Maintains Buy Rating	MT
02-09	BNP Paribas Exane Adjusts Price Target on AbbVie to $213 From $203, Maintains Neutral Rating	MT
02-05	Evercore ISI Adjusts Price Target on AbbVie to $228 From $232, Maintains Outperform Rating	MT
02-05	Goldman Sachs Adjusts Price Target on AbbVie to $240 From $223, Maintains Neutral Rating	MT
02-05	UBS Adjusts AbbVie Price Target to $230 From $240, Maintains Neutral Rating	MT
02-05	Morgan Stanley Lifts Price Target on AbbVie to $270 From $269, Keeps Overweight Rating	MT
02-04	Evercore ISI Adjusts AbbVie Price Target to $228 From $232, Maintains Outperform Rating	MT
01-27	Citigroup Adjusts Price Target on AbbVie to $230 From $235, Maintains Neutral Rating	MT
01-20	Berenberg Lifts Price Target on AbbVie to $275 From $270, Keeps Buy Rating	MT
01-19	MedinCell S.A.: One to Watch Today
01-12	Leerink Partners Adjusts AbbVie Price Target to $245 From $243, Maintains Outperform Rating	MT
01-08	Rothschild & Co Redburn Adjusts AbbVie Price Target to $265 From $258, Maintains Buy Rating	MT
01-08	Wolfe Research Downgrades AbbVie to Peer Perform From Outperform	MT
01-07	UBS Adjusts Price Target on AbbVie to $240 From $220, Maintains Neutral Rating	MT